Merus N.V. (MRUS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Merus N.V. (MRUS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

39.00

-1.45 (-3.58%)

At close: Jan 14, 2025, 3:59 PM

39.01

0.01%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	38
Market Cap	2.67B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.72
PE Ratio (ttm)	-10.48
Forward PE	n/a
Analyst	Buy

Ask	40.67
Volume	1,008,817
Avg. Volume (20D)	560,991
Open	40.62
Previous Close	40.45
Day's Range	38.63 - 40.62
52-Week Range	31.27 - 61.61
Beta	undefined

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 19, 2016

Employees 172

Stock Exchange NASDAQ

Ticker Symbol MRUS

Website https://www.merus.nl

Analyst Forecast

According to 11 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 117.95% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Merus N.V. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $8.95M, reflecting a 0.12% YoY growth and earnings per share of -0.94, making a -13.76% decrease YoY.

Why Price Moved

1 day ago · Source New

-7.75%

Merus shares are trading lower. The company announ... Unlock content with Pro Subscription

1 month ago · Source

+8.23%

Merus shares are trading higher after the company announced it entered into an agreement to exclusively license the right to Ptx the right to commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive cancer in the US.

News

1 month ago · benzinga.com

Merus Scores Its First FDA Approval For Lung Cancer Drug

On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC...

1 month ago · schaeffersresearch.com

Biotech Stock Boosted on Brand-New 'Buy' Rating

Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating.

2 months ago · seekingalpha.com

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promis...

2 months ago · zacks.com

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago.